Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Carter

Showing results (1161-1170 of 1,189) with videos related to

Pageof 119
Sort By:
Nature Biotechnology|November 4, 2000
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivoA B Shanafelt, Y Lin, M C Shanafelt, et al.
Nature Methods|August 29, 2017
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissuesM Ryan Corces, Alexandro E Trevino, Emily G Hamilton, et al.
Cancer Research|October 5, 2001
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancerD W Rusnak, K Affleck, S G Cockerill, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 14, 2022
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative GroupGregor Hoermann, Karl Sotlar, Mohamad Jawhar, et al.
The Journal of Allergy and Clinical Immunology|March 22, 2021
Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator ConferenceJason Gotlib, Tracy I George, Melody C Carter, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 31, 2024
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNMPeter Valent, Karin Hartmann, Gregor Hoermann, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM ConsortiumPolina Pyatilova, Cem Akin, Iván Alvarez-Twose, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM ConsortiumPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Juliana Schwaab, William Shomali, et al.
Pageof 119

Showing results (1161-1170 of 1,189) with videos related to

Sort By:
Pageof 119
Nature Biotechnology|November 4, 2000
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivoA B Shanafelt, Y Lin, M C Shanafelt, et al.
Nature Methods|August 29, 2017
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissuesM Ryan Corces, Alexandro E Trevino, Emily G Hamilton, et al.
Cancer Research|October 5, 2001
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancerD W Rusnak, K Affleck, S G Cockerill, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 14, 2022
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative GroupGregor Hoermann, Karl Sotlar, Mohamad Jawhar, et al.
The Journal of Allergy and Clinical Immunology|March 22, 2021
Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator ConferenceJason Gotlib, Tracy I George, Melody C Carter, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 31, 2024
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNMPeter Valent, Karin Hartmann, Gregor Hoermann, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM ConsortiumPolina Pyatilova, Cem Akin, Iván Alvarez-Twose, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM ConsortiumPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Juliana Schwaab, William Shomali, et al.
Pageof 119